{"denoms":[{"counts":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"106"}],"units":"Participants"}],"groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"BG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"BG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"BG002","title":"Phase 2 (Japan Population)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.42","value":"60.9"},{"groupId":"BG001","spread":"9.09","value":"62.5"},{"groupId":"BG002","spread":"8.87","value":"58.9"},{"groupId":"BG003","spread":"8.42","value":"61.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"44"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"62"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"10"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"17"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"69"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"8"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"9"}]}],"title":"Japan"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"97"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"All treated analysis set included all participants who received JNJ-68284528 infusion."}